SIGA Technologies, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SIGA research report →
Price Chart
About the company
SIGA Technologies, Inc. is a pharmaceutical company with commercialized products, specializing in the health security and infectious disease sectors across the United States. A core offering is TPOXX, an oral antiviral drug formulated to combat human smallpox, a condition caused by the variola virus.
- CEO
- Diem Nguyen
- IPO
- 1997
- Employees
- 49
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on SIGA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $172.45M
- P/E
- 414.06
- Fwd P/E
- 1.41
- PEG
- -3.80
- P/S
- 3.64
- P/B
- 1.17
- EV/EBITDA
- -34.23
- Div Yield
- 22.64%
- Gross Margin
- 54.03%
- Op Margin
- -14.20%
- Net Margin
- 1.37%
- ROE
- 0.42%
- ROIC
- 1.21%
Latest fiscal year · YoY change
- Revenue
- $94.60M-31.8%
- Gross Profit
- $64.87M-39.6%
- Op Income
- $23.70M
- Net Income
- $23.30M-60.7%
- EPS
- $0.33-60.2%
- OCF Growth
- -10.8%
- FCF Growth
- -11.5%
- 52W High
- $7.11
- 52W Low
- $2.30
- 50D MA
- $3.14
- 200D MA
- $4.12
- Beta
- 1.02
- RSI (14)
- 31
- Avg Volume
- 629.28K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
SIGA said its core U.S. procurement timing remains uncertain, but a new Canadian contract and strong cash position support the long-term smallpox preparedness story.· November 9, 2026
- Completed final product delivery under the BARDA 19C contract, ending those U.S. product obligations.
- Signed a new Canada Department of National Defence contract worth up to about $15 million, with about $9 million firm over three years and up to $6 million in options.
- Management still expects a new U.S. government procurement contract eventually, but said timing remains uncertain.
- Pediatric formulation phase I results are expected by year-end; the PEP supplemental NDA timeline slipped to 2028 after FDA requested additional validation work.
- SIGA ended the quarter with $116 million in cash and no debt.
For the first nine months of 2026, SIGA reported product revenues of approximately $42 million, including about $26 million of IV TPOXX deliveries to the U.S. Strategic National Stockpile and about $13 million of international sales to two customers. Research and development revenue was approximately $7 million for the nine months, including about $1 million in the third quarter. Pre-tax operating income for the nine months was approximately $2 million, while third-quarter pre-tax operating loss was approximately $7 million. Net income for the nine months was approximately $6 million, versus a third-quarter net loss of approximately $3 million. Fully diluted EPS was $0.09 for the nine months and a loss of $0.04 per share for the quarter. Guidance/commentary: management expects phase I pediatric formulation results by year end; deliveries under the Canadian contract are expected to start in 2027; the supplemental NDA for PEP is now expected in 2028; and the timing of a new U.S. procurement award remains uncertain, though management still believes one will be awarded.
Diem Nguyen framed the quarter around SIGA’s mission to keep governments prepared for smallpox and other biological threats, emphasizing that geopolitical tensions and AI are increasing the threat landscape. She highlighted completion of the BARDA 19C obligations, the new Canadian contract, and ongoing international discussions as evidence that the company remains relevant globally. Her tone was steady and optimistic about the long-term preparedness case, but candid that government procurement is slower and less predictable than in the past.
Dan Luckshire emphasized the company’s “variable rhythm” and said most of the nine-month revenue was recognized in the second quarter. He quantified the year-to-date mix as roughly $26 million from U.S. Strategic National Stockpile IV TPOXX deliveries and about $13 million from international sales, with no product sales in the third quarter. He also noted $7 million of R&D revenue year to date, a $2 million pre-tax operating income for the nine months, and a quarter-end cash balance of about $116 million with no debt.
Analysts focused on whether the Canada contract was the international opportunity referenced last quarter, and management confirmed it was, while also saying another international contract is in advanced stages. On delivery timing, management said the Canadian firm orders are spread evenly across the first three fiscal years, deliveries start in 2027, and option orders can be placed at Canada’s discretion over the five-year term. Questions about U.S. midterm election implications were met with management saying biodefense has bipartisan support and the election should not materially change the RFP trajectory beyond a normal transition period. On Europe, management said demand is growing but the market remains vaccine-centric, that the mpox label change may affect timing but not the long-term stockpiling opportunity, and that SIGA has renewed TPOXX filings in Europe and the U.K.
The call showed SIGA still has commercial and government-relevance momentum: it closed a new multi-year Canadian contract, has another international deal in late-stage discussions, and continues to believe a new U.S. procurement contract will be awarded. Management also pointed to a strong balance sheet, ongoing pediatric and PEP development, and continued bipartisan support for biodefense.
The biggest risk remains timing: management said the new U.S. government contract award is still uncertain and slower than in the past, and the PEP supplemental NDA timeline was pushed to 2028 after FDA requested more work. Third-quarter product sales were zero, underscoring the lumpiness of the business, and Europe still appears to be a slower, more vaccine-centric market where change takes time.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 57.2%
- Shares Outstanding
- 71.86M
- Float Shares
- 41.12M
of shares held by institutions
167 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 5.47M | ▲ 1.28M |
| Vanguard Group Inc | 2.72M | ▲ 67.81K |
| Dimensional Fund Advisors LP | 2.01M | ▼ 707.96K |
| Vanguard Capital Management LLC | 1.72M | ▲ 8.28K |
| American Century Companies Inc | 1.43M | ▼ 75.95K |
| First Wilshire Securities Management Inc | 1.41M | ▲ 65.13K |
| Morgan Stanley | 1.27M | ▲ 849.03K |
| State Street Corp | 1.17M | ▲ 32.82K |
| Qube Research & Technologies Ltd | 1.16M | ▲ 423.30K |
| Arrowstreet Capital, Limited Partnership | 1.14M | ▼ 334.91K |
| Geode Capital Management, LLC | 1.12M | ▼ 296.80K |
| Hotchkis & Wiley Capital Management LLC | 1.08M | ▲ 164.88K |
Held by 148 ETFs
Biggest fund positions in SIGA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 9, 26 | Marshall Joseph W III | other | 24,116 |
| Jun 9, 26 | Marshall Joseph W III | sell | 7,235 |
| Jun 9, 26 | Marshall Joseph W III | other | 34,169 |
| Jun 9, 26 | Marshall Joseph W III | other | 24,116 |
| Jun 9, 26 | KEANE JOHN M | other | 34,169 |
| Jun 9, 26 | KEANE JOHN M | other | 24,116 |
| Jun 9, 26 | KEANE JOHN M | sell | 7,235 |
| Jun 9, 26 | KEANE JOHN M | other | 24,116 |
| Jun 9, 26 | Ford Harold Eugene Jr. | other | 24,116 |
| Jun 9, 26 | Ford Harold Eugene Jr. | sell | 7,235 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SIGA coverage
Recent articles, reports, and earnings notes.
No research on SIGA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SIGA report →Financial Review: Vanda Pharmaceuticals (NASDAQ:VNDA) vs. Siga Technologies (NASDAQ:SIGA)
defenseworld.net · Nov 14
SIGA Technologies, Inc. (SIGA) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
What Siga Technologies (SIGA) Said on Its Q3 Earnings Call
marketbeat.com · Nov 9
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2026
globenewswire.com · Nov 9
SIGA Announces Retirement of Chief Scientific Officer Dennis Hruby, Ph.D.
globenewswire.com · Nov 9
SIGA to Host Business Update Call on November 9, 2026, Following Release of Third-Quarter 2026 Financial Results
globenewswire.com · Oct 29
SIGA Secures Contract Valued at Up to $15 Million from Canadian Department of National Defence to Purchase TPOXX®
globenewswire.com · Oct 28
Dimensional Fund Advisors LP Grows Stock Holdings in Siga Technologies Inc. $SIGA
defenseworld.net · Aug 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.